Skip to main content

Table 2 PCR-adjusted and unadjusted cure rates of the study participants at day-42 at Dafra health district medical centre, Burkina Faso, 2008–2010

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Outcome: day 42

AL

ASAQ

Difference (CI 95%)

p-value

Variables

PCR corrected efficacy outcome—no. (%)

Per protocol population (N = 420) n (%)

213

207

 Adequate clinical and parasitological response

194 (91.1)

203 (98.1)

− 7 (− 11.0 to − 2.7)

< 0.0006

 Early treatment failure

0 (0.0)

0 (0)

 Late clinical failure

0 (0.0)

0 (0)

 Late parasitological failure

19 (8.9)

4 (1.9)

 Total number of failure

19 (8.9)

4 (1.9)

Not corrected for reinfection n (%)

 Adequate clinical and parasitological response

106 (49.8)

147 (71.0)

− 22 (− 31.1 to − 12.9)

< 0.0001

 Early treatment failure

0 (0)

0 (0)

 Late clinical failure

32 (15.0)

22 (10.6)

 Late parasitological failure

75 (35.2)

38 (18.4)

 Total number of failure

107 (50.2)

60 (28.9)

Intent-to-treat population (N = 440)

220

220

 PCR-adjusted

 Total number of patients n

194

203

  

 Adequate clinical and parasitological response % (95% CI)

88.2 (83.2–91.8

92.3 (87.9–95.2)

− 4.1 (− 9.8 to − 1.5)

0.148

 PCR-unadjusted

 Total number of patients n

106

147

 Adequate clinical and parasitological response % (95% CI)

48.2 (41.6–54.8)

66.8 (60.3–72.8)

− 18.6 (− 27.4 to 9.4)

< 0.001

  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, CI 95% confident interval, n number, % percentage